Published in Am J Gastroenterol on February 01, 1998
Excess gastric ulcers are associated with alendronate therapy. Am J Gastroenterol (1998) 0.77
Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Am J Gastroenterol (1997) 2.11
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (1997) 3.58
Measuring fitness in healthy older adults: the Health ABC Long Distance Corridor Walk. J Am Geriatr Soc (2001) 3.39
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest (1997) 2.33
Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med (1998) 2.22
Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost (2011) 2.18
Race and sex effects on the association between muscle strength, soft tissue, and bone mineral density in healthy elders: the Health, Aging, and Body Composition Study. J Bone Miner Res (2001) 2.16
Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax (2005) 2.08
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med (1996) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med (1998) 1.96
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol (1995) 1.94
Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol (2001) 1.91
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med (1998) 1.84
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Airflow limitation is underrecognized in well-functioning older people. J Am Geriatr Soc (2001) 1.76
Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem J (1999) 1.72
Association between aortic calcification and total and cardiovascular mortality in older women. J Intern Med (2007) 1.70
Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma. Gastroenterology (1992) 1.61
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice. J Thromb Haemost (2010) 1.57
A revised model of platelet aggregation. J Clin Invest (2000) 1.54
Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther (2004) 1.53
Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int (2006) 1.52
Osteoporosis: association of recent fractures with quantitative US findings. Radiology (1996) 1.50
Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group. J Neurooncol (1998) 1.48
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med (2000) 1.47
Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) (1985) 1.45
Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res (2001) 1.45
Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet (1985) 1.42
The platelet glycoprotein GPIbbeta intracellular domain participates in von Willebrand factor induced-filopodia formation independently of the Ser 166 phosphorylation site. J Thromb Haemost (2009) 1.41
Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab (1998) 1.41
Further evidence that fibrillar collagen is unable to promote platelet shape change and aggregation in the absence of secondary agonists. J Thromb Haemost (2005) 1.40
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol (1987) 1.34
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant (2011) 1.32
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
Incidence and risk factors for a second hip fracture in elderly women. The Study of Osteoporotic Fractures. Osteoporos Int (2003) 1.28
Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol (1989) 1.28
Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int (2000) 1.28
Genetic markers for ancestry are correlated with body composition traits in older African Americans. Osteoporos Int (2007) 1.27
A preoperative decolonization protocol for staphylococcus aureus prevents orthopaedic infections. Clin Orthop Relat Res (2008) 1.26
Urology in a modern health centre. Br Med J (1975) 1.26
CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. J Virol (1997) 1.26
Precipitin activity of rabbit macroglobulin antibody. Immunochemistry (1966) 1.25
An endoscopic evaluation of the effects of non-steroidal anti-inflammatory drugs on the gastric mucosa. Gastrointest Endosc (1975) 1.23
Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res (1998) 1.22
Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med (1996) 1.22
Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol (1985) 1.20
Diphosphonates and phosphate homoeostasis in man. Clin Sci (Lond) (1988) 1.20
Creutzfeldt-Jakob disease presenting as progressive aphasia. J Natl Med Assoc (1985) 1.18
Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy (2008) 1.17
Type 2 diabetes in older well-functioning people: who is undiagnosed? Data from the Health, Aging, and Body Composition study. Diabetes Care (2001) 1.16
Brain tumors in childhood. Childs Brain (1979) 1.15
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab (1996) 1.15
Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J (Clin Res Ed) (1984) 1.14
Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost (2009) 1.14
The nature of antibodies synthesized during the immune response to Leptospira biflexa. J Immunol (1965) 1.14
Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and Do not exhibit a Bernard-Soulier phenotype. Blood (1999) 1.14
Body size accounts for most differences in bone density between Asian and Caucasian women. The EPIC (Early Postmenopausal Interventional Cohort) Study Group. Calcif Tissue Int (1996) 1.13
An immunophenotypic survey of malignant melanomas. Histopathology (1993) 1.13
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol (1996) 1.13
Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone (1987) 1.12
The syndrome of occult rupture of the spleen. Arch Surg (1969) 1.12
Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study. Calcif Tissue Int (2006) 1.12
The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab (1993) 1.11
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy (2008) 1.11
Endogenous GD3 ganglioside induces apoptosis in U-1242 MG glioma cells. J Neurochem (2006) 1.10
BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood (2001) 1.10
Clinical and biochemical abnormalities in coppersmiths exposed to cadmium. Lancet (1976) 1.10
Glycoprotein (GP) Ib-IX-transfected cells roll on a von Willebrand factor matrix under flow. Importance of the GPib/actin-binding protein (ABP-280) interaction in maintaining adhesion under high shear. J Biol Chem (1999) 1.09
Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem (1993) 1.08
Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int (2007) 1.07
Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J (Clin Res Ed) (1984) 1.07
The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem (1999) 1.06
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia (2004) 1.06
CD38: a multi-lineage cell activation molecule with a split personality. Int J Clin Lab Res (1992) 1.06
Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab (1999) 1.05
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant (2009) 1.05
Case-only analysis of treatment-covariate interactions in clinical trials. Biometrics (2006) 1.05
Psychological deficit. Annu Rev Psychol (1966) 1.04
Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res (1998) 1.04
Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry. Biochemistry (2000) 1.03
Effective short term treatment of Paget's disease with oral etidronate. Br Med J (Clin Res Ed) (1986) 1.03
Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeost Agents (2001) 1.03
Treatment of high-grade spinal cord astrocytoma of childhood with "8-in-1" chemotherapy and radiotherapy: a pilot study of CCG-945. Children's Cancer Group. J Neurosurg (1998) 1.02
Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res (1997) 1.02
Intracranial chordoma in infancy. Case report. J Neurosurg (1975) 1.02
Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol (2001) 1.02
Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst (2001) 1.01
Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1996) 1.01
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone (1996) 1.00
Relation of axon membrane to myelin membrane in sciatic nerve during development: comparison of morphological and chemical parameters. Brain Res (1976) 1.00
Sympathetic innervation of murine thymus and spleen: evidence for a functional link between the nervous and immune systems. Brain Res Bull (1981) 1.00